Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

By E. Weisberg, P. Manley, S. Cowan-Jacob, Andreas Hochhaus, J. Griffin. Nature Reviews. Cancer, 2007

644 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/039e931ad5c62b27f7166e37b7f1c8d687ad820b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Marcus Bantscheff
2. A. Bauer
3. B. Kuster
4. C. Hopf
5. D. Eberhard
6. G. Drewes
7. G. Neubauer
8. N. Ramsden

Citations in the corpus

• Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors (2007, methodology): “We apply the methodology to three drugs targeting the oncogenic BCR-ABL kinase, which induces chronic myelogenous leukemi”